Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03349892 · ClinicalTrials.gov registry record · NA
Stereotactic Ablative Radiotherapy for Refractory Ventricular Tachycardia
A NA study, sponsored by University of California, Los Angeles.
- Completed
- Registry status
- NA
- Development phase
- 1
- Enrollment target
NCT03349892 is a NA study that has completed, run by University of California, Los Angeles. The registered enrollment target is 1 participants.
The verdict
NCT03349892, a NA study, has completed, sponsored by University of California, Los Angeles.
- COMPLETED
- Registry status
- NA
- Development phase
- 1 participants
- Enrollment target
Study Summary
Single arm, phase Ib/2a dose escalation study with an expansion cohort to determine the maximal tolerated dose (MTD) for stereotactic ablative radiotherapy of targets in the cardiac myocardium and to make a preliminary assessment of the efficacy of the treatment. The dose escalation will be guided by Time-to-Event Continual Reassessment Method (TITE-CRM) to ensure more patients will be spared dose limiting toxicities and more patients will be entered on the dose level that will be chosen as minimal dose of maximal effect. This design also allows for continual accrual of patients when delayed adverse events may be observed.
Interventions
- RADIATION Stereotactic Ablative Radiotherapy (SABR)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2017-04-01 |
| Est. Completion | 2019-08-06 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03349892
The ClinicalTrials.gov registry entry for NCT03349892 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Los Angeles, which has 897 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Stereotactic Ablative Radiotherapy (SABR) is the first listed.
NCT03349892 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03349892 about?
NCT03349892 is a clinical study titled "Stereotactic Ablative Radiotherapy for Refractory Ventricular Tachycardia". Single arm, phase Ib/2a dose escalation study with an expansion cohort to determine the maximal tolerated dose (MTD) for stereotactic ablative radiotherapy of targets in the cardiac myocardium and to make a preliminary assessment of the efficacy of the treatment. The dose escalation will be guided b...
What is the current status of trial NCT03349892?
This trial is currently completed. It is a NA study. The enrollment target is 1 participants. The study started on 2017-04-01. Estimated completion is 2019-08-06.
What interventions are being tested in trial NCT03349892?
The interventions under investigation include: Stereotactic Ablative Radiotherapy (SABR) (RADIATION).
Who is sponsoring clinical trial NCT03349892?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.